Asston Pharmaceuticals Ltd.

BSE: 544445

Asston Pharmaceuticals Live Share Price Today, Share Analysis and Chart

Name: Asston Pharmaceuticals Ltd.: Is Infosys Ltd. worth buying?
Item: Asston Pharmaceuticals Ltd.
Rating: 2.44216675
Author: Trendlyne DVM scores

aboutAsston Pharmaceuticals Ltd. is a pharmaceutical company based in Navi Mumbai, India, primarily involved in the manufacturing and supply of medicinal products. The company focuses on the production of pharmaceutical tablets, operating with a substanti... Read More

-2.55(-1.69%)

New 52W High in past week

1,000

BSE Volume

BSE 03 Nov, 2026 10:43 AM (IST)

Portfolio

Alert

My Notes

- / 100

75.5 / 100

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

7Positive8Negative

46.7%Pass in checklist

045

100

Check P/E Buy Sell Zone

Strong Sell Zone

100.0 % into P/E buy sell zone

% time spent below current P/E

020406080100

Strong upside potential

Gains already realized

Asston Pharmaceuticals Stock Price Analysis

Day Price Range -1.7% 1 Day return	148 (LTP) 148148 LowHigh
Week Price Range 10.1% 1 Week return	148 (LTP) 130153.4 LowHigh
Month Price Range 52.0% 1 Month return	148 (LTP) 90.2153.4 LowHigh
52 Week Price Range 78.1% 1 Year return	148 (LTP) 60153.4 LowHigh

View full Price History/Seasonality

Competitors/Peers

Annual

Balance Sheet

Ratios

Cash Flow

Documents

Asston Pharmaceuticals annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Asston Pharmaceuticals Mar-2026 Annual Revenue is Rs 32 Cr which is growth of 23.3% YoY.
NEGATIVE
Annual Net Profit Asston Pharmaceuticals Mar-2026 Annual Net Profit is Rs 4 Cr which is growth of -10.6% YoY.

Asston Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '21	Mar '20
SR_A Total Rev. Ann. ⌄	63.7%	31.3%	31.6	25.6	15.8	7.2	8.1	2.5
TotalOperatingRevenues_A Operating Rev. Ann.	57.7%	26.1%	25.5	25	15.6	6.5	8	2.5
OI_A Other Income Ann.	105.8%	127.5%	6.1	0.6	0.3	0.7	0.1	0
OEXPNS_A Operating Exp. Ann.	73.2%	26.9%	26	18.9	13	5	7.9	2.5
OEXPNS_A Operating Exp. Ann.	73.2%	26.9%	26	18.9	13	5	7.9	2.5
OP_A Operating Profit Ann.	-	-	-0.6	6.2	2.6	1.5	0.2	0
OPMPCT_A OPM Ann. %	-	-	-1.79%	24.05%	16.07%	21.09%	2.06%	1.14%
TotalExpenses_A Total Exp. Ann. ⌄	67%	27.5%	27	19.9	14	5.8	8	2.5
OtherExpenses_A Other Exp. Ann.	76%	23.4%	6	3.2	2.4	1.1	2.1	0.5
EmployeeBenefitExpenses_A Employee Exp. Ann.	63%	45.4%	2.6	1.5	0.9	0.6	0.4	0.2
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	36.5%	79.6%	5.6	6.7	2.8	2.2	0.3	0.1
EBIDTPCT_A EBITDA Ann. margin %	-16.5%	40.8%	17.57%	26.28%	17.68%	30.18%	3.18%	2.14%
INT_A Interest Ann.	-5%	43.1%	0.6	1	0.9	0.7	0.1	0
DEP_A Depr.	-	-	0.3	0.1	0.1	0	0
PBT_A PBT Ann.	48.7%	115.1%	4.6	5.7	1.8	1.4	0.1	0
TAX_A Tax Ann.	20.5%	-	0.7	1.4	0.5	0.4	0
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	52.5%	108.1%	3.9	4.3	1.4	1.1	0.1	0
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	52.5%	108.1%	3.9	4.3	1.4	1.1	0.1	0
NETPCT_A NPM Ann. %	-2.1%	67.8%	15.17%	17.27%	8.72%	16.16%	1.14%	1.40%
EPS_adj_A EPS Adj. latest Ann.	55.4%	114.1%	4.5	5.1	1.6	1.2	0.1	0

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

Total Rev. Ann.

1Y CHG

23.4%

2Y CAGR

41.4%

3Y CAGR

63.7%

5Y CAGR

31.3%

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

-9.3%

2Y CAGR

66.9%

3Y CAGR

52.5%

5Y CAGR

108.1%

Net Profit Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

37.6%

2Y CAGR

41.4%

3Y CAGR

73.2%

5Y CAGR

26.9%

Operating Expenses Annual Cr growth is lower than historical averages.

Asston Pharmaceuticals Technical Analysis

Asston Pharmaceuticals EMA & SMA

Bullish+8

8 bullish, 0 bearish

Bullish8

Bearish0

5 Day	146.1
10 Day	136.9
12 Day	133.8
20 Day	124.9

26 Day	120.5
50 Day	109.7
100 Day	99.1
200 Day	94.7

Asston Pharmaceuticals Delivery And Volume

Daily Avg. Delivery Volume %

02 Nov, 2026100.0%

Week100.0%

Month100.0%

Asston Pharmaceuticals Active Candlesticks

Inside Uptrend Matching Low

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

Asston Pharmaceuticals Resistance and Support

150.20

Pivot

First Resistance	153.4
Second Resistance	156.2
Third Resistance	159.3

First Support	147.4
Second Support	144.3
Third Support	141.5

Day RSI	85.2
Day MACD	13.3
Day MFI	99.2
Day MACD Signal Line	8.9

Asston Pharmaceuticals Beta

1 Month	-1.0
1 Year	-0.1

3 Month	-0.4
3 Year	-

Asston Pharmaceuticals Price Change Analysis

↑52.0%

Over 1 Month

LowHigh

90.3153.4

↑120.9%

Over 3 Months

LowHigh

66.5153.4

↑82.9%

Over 6 Months

LowHigh

60153.4

↑78.1%

Over 1 Year

LowHigh

60153.4

Asston Pharmaceuticals Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Saili Jayaram More	Promoter	1,852,856	17.0 %
Vijay Rathee	Public	1,317,391	12.1 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Asston Pharmaceuticals Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
PRASHANT P SAWANT	Bulk	Purchase	27 Oct 2026	140.44	61,000	BSE
PRASHANT P SAWANT	Bulk	Purchase	23 Oct 2026	129.16	46,000	BSE
PRAKRUTI R PALI	Bulk	Purchase	01 Sep 2026	123.04	51,000	BSE
SNEHLATA MANOJ KATHOTIA	Bulk	Purchase	31 Aug 2026	119.10	43,000	BSE
PRAKRUTI R PALI	Bulk	Purchase	31 Aug 2026	123.88	100,000	BSE
PRAKRUTI R PALI	Bulk	Purchase	28 Aug 2026	112.81	164,000	BSE
PRAKRUTI R PALI	Bulk	Purchase	27 Aug 2026	103.69	240,000	BSE
PRAKRUTI R PALI	Bulk	Purchase	26 Aug 2026	95.59	138,000	BSE
VANITA ANILKUMAR KUMBHARE	Bulk	Sell	20 Aug 2026	81.04	70,000	BSE
SNEHLATA MANOJ KATHOTIA	Bulk	Purchase	20 Aug 2026	81.68	67,000	BSE

All deals

All insider trades

Asston Pharmaceuticals Corporate Actions

Asston Pharmaceuticals Board Meetings

Asston Pharmaceuticals past and upcoming board meetings.

#Ex-Date	Purpose	Notes
113 Oct 2026	Others	-
204 Sep 2026	A.G.M.	-
302 Jul 2026	Preferential Issue of shares & Others	To consider other business matters.
429 May 2026	Audited Results	-
530 Mar 2026	Notice of EGM & Others	Inter-alia, to consider 1. Appointment of Mr. Sumit Pawar as Chief Financial Officer. 2. Appointment of Mr. Yashvardhan Tupe as Additional Non-Executive Director. 3. Other business matters.

All Corporate Actions

Asston Pharmaceuticals Corporate Filings

Asston Pharmaceuticals BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Date	Announcement Title	Details	Links
14 Oct 2026	Asston Pharmaceuticals Ltd - 544445 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation 2018	PDF
13 Oct 2026	Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Change in Registered Office Address	Change in registered office address	PDF
13 Oct 2026	Asston Pharmaceuticals Ltd - 544445 - Board Meeting Outcome for Outcome Of The Board Held On 13Th October, 2026.	Outcome of the Board held on 13th October, 2026.	PDF
06 Oct 2026	Asston Pharmaceuticals Ltd - 544445 - Board Meeting Intimation for To Consider And Approve The Following Matters As Attached	Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/10/2026 ,inter alia, to consider and approve matters as attached	PDF
01 Oct 2026	Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Change in Management	Change in Management	PDF

VIEW ALL

Asston Pharmaceuticals - Company Profile

Asston Pharmaceuticals Management Structure

Asston Pharmaceuticals management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF
Saili Jayaram More	Whole Time Director,Chief Executive Officer	-	Mar 25
Rishi Upadhyay	Company Secretary,Compliance Officer	-	Mar 25
Sumit Pawar	Chief Financial Officer	-	Mar 25

Asston Pharmaceuticals Board of Directors

Asston Pharmaceuticals Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
Ashish Narayan Sakalkar	Managing Director	-	Mar 25
Saili Jayaram More	Whole Time Director & CEO	-	Mar 25
Sachin Chandrakant Badakh	Non Executive Director	-	Mar 25
Rishabh Kumar Jain	Independent Non Exe. Director	-	Mar 25
Vijaya Shahpurkar	Independent Non Exe. Director	-	Mar 25
Vandana Mishra	Company Sec. & Compli. Officer	-	Mar 25
Yashvardhan Tupe	Additional Director	-	Mar 25
Sandip Sharma	Additional Director	-	Mar 25

About

Website: www.asstonpharmaceuticals.com

About the company - Business Profile

Asston Pharmaceuticals Ltd. is a pharmaceutical company based in Navi Mumbai, India, primarily involved in the manufacturing and supply of medicinal products. The company focuses on the production of pharmaceutical tablets, operating with a substantial manufacturing capacity and high utilization rates to meet growing market demand. It maintains a presence in the domestic market, serving as a manufacturer for both captive requirements and external demand.

Key Points

Key Facts:
- Founded: 2019 (Incorporated as Asston Pharmaceuticals Private Limited).
- Headquarters: Navi Mumbai, Maharashtra, India.
- Stock Listing: Listed on the BSE (Stock code 12541944).
- Status: Formerly a private limited company, now a public limited company.
Operations and Resources:
- Facilities: The primary manufacturing facility is located at MIDC Anandnagar, Ambernath, Maharashtra.
- Capacity: Current installed capacity is 5–6 crore tablets per month.
- Utilization: The facility operates at an approximately 80% capacity utilization level as of late 2025.
Market and Significance:
- The company serves the growing pharmaceutical demand in India, focusing on tablet-based formulations.
- Its strategic importance lies in its role as a supply chain partner for medicinal products, addressing both captive and market-driven needs.
Business Model and Core Competencies:
- Model: Asston operates a manufacturing-heavy model, producing large volumes of tablets. It leverages its specialized facility in Ambernath to maintain high throughput and quality control.
- Core Strength: The company is particularly proficient in high-volume tablet manufacturing and efficient facility management, maintaining high utilization rates while planning for aggressive capacity expansion.
Revenue and Financials (FY 2024-25):
- Annual Revenue: Total income for the year ended March 31, 2025, was ₹2,561.02 Lakhs.
- Profitability: Net profit for FY 2024-25 stood at ₹116.31 Lakhs.
- Segment Breakdown: Revenue is primarily derived from the "Pharmaceuticals" business segment.
- Geographical Breakdown: Operations and sales are predominantly focused within India.
Strategic Initiatives and Future Outlook:
- Capacity Expansion: The company has initiated a major expansion plan to increase its tablet manufacturing capacity from 5–6 crore to 14–15 crore tablets per month.
- Investment: An investment of approximately ₹600 Lakhs is earmarked for this addition, expected to be completed by Q4 FY 2025-26.
- Financing: The expansion is planned to be funded through internal accruals and proceeds from an Initial Public Offer (IPO).
- Outlook: The management is focusing on scaling production to capture a larger share of the growing medicinal product market.

References

Result Nov 2025

Asston Pharmaceuticals FAQ

Asston Pharmaceuticals today is trading in the red, down by 1.69% at ₹148.

Asston Pharmaceuticals is currently trading down 1.69% on an intraday basis. In the past week the stock rose 10.09%. Stock has been up 120.9% in the past quarter and rose 78.1% in the past year. You can view this in the share price history/seasonality section.

Asston Pharmaceuticals is listed on BSE with ticker 544445. It's currently trading on BSE at a share price of ₹148.

The market cap of Asston Pharmaceuticals is ₹125.98 Cr. as of Nov 03, 2026.

Asston Pharmaceuticals has never announced any dividend since the time of its listing on the BSE exchange.

Asston Pharmaceuticals has never issued stock splits or bonus shares since the time of its listing on the BSE exchange.

Asston Pharmaceuticals reported ₹31.58 Cr. in revenue, ₹3.87 Cr. in net profit, and ₹5.55 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

There are no analyst predictions for stock price target for Asston Pharmaceuticals.

The PE ratio of Asston Pharmaceuticals is 32.59 as of Nov 03, 2026.

The PB ratio of Asston Pharmaceuticals is 3.24 as of Nov 03, 2026.

There are no analyst reports for Asston Pharmaceuticals.

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Asston Pharmaceuticals Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Asston Pharmaceuticals Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Asston Pharmaceuticals - Annual

Asston Pharmaceuticals annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue Asston Pharmaceuticals Mar-2026 Annual Revenue is Rs 32 Cr which is growth of 23.3% YoY.

Annual Net Profit Asston Pharmaceuticals Mar-2026 Annual Net Profit is Rs 4 Cr which is growth of -10.6% YoY.

Asston Pharmaceuticals Technical Analysis

Asston Pharmaceuticals EMA & SMA

Asston Pharmaceuticals Delivery And Volume

Asston Pharmaceuticals Active Candlesticks

Asston Pharmaceuticals Resistance and Support

Asston Pharmaceuticals Beta

Asston Pharmaceuticals Price Change Analysis

Asston Pharmaceuticals Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Asston Pharmaceuticals Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Insider Trading & SAST

Asston Pharmaceuticals Corporate Actions

Asston Pharmaceuticals Board Meetings

Asston Pharmaceuticals past and upcoming board meetings.

Asston Pharmaceuticals Corporate Filings

Asston Pharmaceuticals BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Asston Pharmaceuticals - Company Profile

Asston Pharmaceuticals Management Structure

Asston Pharmaceuticals management structure with salaries, total experience, and qualifications.

Asston Pharmaceuticals Board of Directors

Asston Pharmaceuticals Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Key Points

References

Asston Pharmaceuticals FAQ

How is Asston Pharmaceuticals today?

Asston Pharmaceuticals today is trading in the red, down by 1.69% at ₹148.

How has Asston Pharmaceuticals performed historically?

Asston Pharmaceuticals is currently trading down 1.69% on an intraday basis. In the past week the stock rose 10.09%. Stock has been up 120.9% in the past quarter and rose 78.1% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of Asston Pharmaceuticals on NSE and BSE exchanges?

Asston Pharmaceuticals is listed on BSE with ticker 544445. It's currently trading on BSE at a share price of ₹148.

What is the market cap of Asston Pharmaceuticals?

The market cap of Asston Pharmaceuticals is ₹125.98 Cr. as of Nov 03, 2026.

When did Asston Pharmaceuticals last pay a dividend, and what has its dividend history been?

Asston Pharmaceuticals has never announced any dividend since the time of its listing on the BSE exchange.

Has Asston Pharmaceuticals issued any bonus shares or share splits recently?

Asston Pharmaceuticals has never issued stock splits or bonus shares since the time of its listing on the BSE exchange.

What do the financial statements and annual reports of Asston Pharmaceuticals Indicate?

Asston Pharmaceuticals reported ₹31.58 Cr. in revenue, ₹3.87 Cr. in net profit, and ₹5.55 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

What is the target share price of Asston Pharmaceuticals according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for Asston Pharmaceuticals.

What is the PE Ratio of Asston Pharmaceuticals?

The PE ratio of Asston Pharmaceuticals is 32.59 as of Nov 03, 2026.

What is the PB Ratio of Asston Pharmaceuticals?

The PB ratio of Asston Pharmaceuticals is 3.24 as of Nov 03, 2026.

Where can I check the latest Research Reports about Asston Pharmaceuticals?

There are no analyst reports for Asston Pharmaceuticals.

How can I be notified of real time alerts about Asston Pharmaceuticals stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.